"Stomach Neoplasms" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Tumors or cancer of the STOMACH.
Descriptor ID |
D013274
|
MeSH Number(s) |
C04.588.274.476.767 C06.301.371.767 C06.405.249.767 C06.405.748.789
|
Concept/Terms |
Stomach Neoplasms- Stomach Neoplasms
- Neoplasm, Stomach
- Stomach Neoplasm
- Neoplasms, Stomach
- Gastric Neoplasms
- Gastric Neoplasm
- Neoplasm, Gastric
- Neoplasms, Gastric
Cancer of Stomach- Cancer of Stomach
- Stomach Cancers
- Gastric Cancer
- Cancer, Gastric
- Cancers, Gastric
- Gastric Cancers
- Stomach Cancer
- Cancer, Stomach
- Cancers, Stomach
- Cancer of the Stomach
|
Below are MeSH descriptors whose meaning is more general than "Stomach Neoplasms".
Below are MeSH descriptors whose meaning is more specific than "Stomach Neoplasms".
This graph shows the total number of publications written about "Stomach Neoplasms" by people in this website by year, and whether "Stomach Neoplasms" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 5 | 2 | 7 |
1995 | 14 | 1 | 15 |
1996 | 13 | 2 | 15 |
1997 | 16 | 3 | 19 |
1998 | 17 | 6 | 23 |
1999 | 28 | 6 | 34 |
2000 | 18 | 5 | 23 |
2001 | 30 | 0 | 30 |
2002 | 31 | 5 | 36 |
2003 | 28 | 8 | 36 |
2004 | 38 | 11 | 49 |
2005 | 46 | 6 | 52 |
2006 | 45 | 9 | 54 |
2007 | 43 | 5 | 48 |
2008 | 28 | 7 | 35 |
2009 | 35 | 8 | 43 |
2010 | 35 | 5 | 40 |
2011 | 38 | 5 | 43 |
2012 | 29 | 5 | 34 |
2013 | 35 | 7 | 42 |
2014 | 40 | 7 | 47 |
2015 | 30 | 4 | 34 |
2016 | 34 | 2 | 36 |
2017 | 45 | 5 | 50 |
2018 | 44 | 3 | 47 |
2019 | 45 | 3 | 48 |
2020 | 59 | 5 | 64 |
2021 | 36 | 3 | 39 |
2022 | 48 | 0 | 48 |
2023 | 50 | 0 | 50 |
2024 | 30 | 6 | 36 |
To return to the timeline,
click here.
Below are the most recent publications written about "Stomach Neoplasms" by people in Profiles.
-
Targeted and combination immunotherapies using biologics for gastric cancer: the state-of-the-art. Expert Opin Biol Ther. 2024 Oct; 24(10):1005-1015.
-
Zolbetuximab in Gastric or Gastroesophageal Junction Adenocarcinoma. N Engl J Med. 2024 Sep 26; 391(12):1159-1162.
-
The road to a world-unified approach to the management of patients with gastric intestinal metaplasia: a review of current guidelines. Gut. 2024 Sep 09; 73(10):1607-1617.
-
From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer. Front Immunol. 2024; 15:1449525.
-
Characteristic endoscopic findings in Helicobacter pylori diagnosis in clinical practice. Expert Rev Gastroenterol Hepatol. 2024 Aug; 18(8):457-472.
-
Health-related quality of life in patients with CLDN18.2-positive, locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma: results from the SPOTLIGHT and GLOW clinical trials. ESMO Open. 2024 Aug; 9(8):103663.
-
SMYD5 methylation of rpL40 links ribosomal output to gastric cancer. Nature. 2024 Aug; 632(8025):656-663.
-
Survival Outcomes in Patients with Resectable Gastric Cancer Treated with Total Neoadjuvant Therapy. Ann Surg Oncol. 2024 Oct; 31(10):6918-6930.
-
Presence of Fusobacterium nucleatum in relation to patient survival and an acidic environment in oesophagogastric junction and gastric cancers. Br J Cancer. 2024 Sep; 131(5):797-807.
-
Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas: The MD Anderson Cancer Center experience. Int J Cancer. 2024 Dec 15; 155(12):2277-2286.